Abacus Medicine Group

Management

The Abacus Medicine Group is headed by our Board of Directors and the Executive Management Team.

Board of Directors

Board Member Jens Albert Harsaae

Jens Albert Harsaae

Chairman of the Board

Board Member Troels Peter Troelsen

Troels Peter Troelsen

Board Member

CEO Flemming Wagner

Flemming Wagner

CEO & majority share holder

Board Member Anders K. Bønding

Anders K. Bønding

Board Member

Board Member Mark Johnston

Mark Johnston

Board Member

Board Member Michala Fischer-Hansen

Michala Fischer-Hansen

Board Member

Executive Management Team

CEO Flemming Wagner

Flemming Wagner

CEO & majority shareholder

Abacus Medicine Group CFO, Maria Addis

Maria Addis

CFO

CLO Lene Beck McCormick

Lene Bech McCormick

CLO

CCO Frederik Heupel

Frederik Heupel

CCO

Allan Dinesen COO of Abacus Medicine

Allan Dinesen

COO

Sune Vorre, CIO

Sune Vorre

CIO

HR Director Marianne Juhl Christensen
Marianne Juhl Christensen

Global P&C Director

Managing Director, Pluripharm

Léon Tinke

Managing Director,
Pluripharm

Managing Director Simon Estcourt

Simon Estcourt

Managing Director,
Abacus Medicine Pharma Services

Board Member Jens Albert Harsaae

Mr. Harsaae joined the Board of Directors of Abacus Medicine in 2017.

Mr. Harsaae is a professional board member with a portfolio of positions as Chairman or member of non-executive/advisory boards in private equity or privately owned companies and start-ups. Previously, Mr. Harsaae was a Partner and the Managing Director for the Boston Consulting Group in Denmark, and Marketing Director for Procter & Gamble. Mr. Harsaae studied finance and marketing at the Aarhus School of Business and holds a master’s degree in economics.

Board Member Troels Peter Troelsen

Mr. Troelsen is a Board Member. He served as Chairman of the Board of Directors from 2009 to 2020.

Mr. Troelsen is a highly experienced board member with more than 30 years of practice as chairman of several companies, extensive experience as CEO in large companies in both Denmark, UK and US, and 20 years of experience as associate professor at Copenhagen Business School with focus on pricing and sports economics. Mr. Troelsen holds a master’s degree in macroeconomics.

CEO Flemming Wagner
Mr. Wagner is CEO and majority shareholder of Abacus Medicine. Prior to founding Abacus Medicine A/S in 2004, Mr. Wagner was the CEO of RAMCON A/S, a company focused on analytical and diagnostic equipment for hospitals and pharmaceutical industries. He holds an Executive MBA from Copenhagen Business School and a master’s degree in biochemistry from University of Copenhagen.
Board Member Anders K. Bønding

Mr. Bønding joined the Board of Directors of Abacus Medicine in 2019.

Mr. Bønding is Founder and Partner at Greystone Capital Partners, and an experienced Chairman and Board member. As former Global Head of Corporate Finance with Danske Bank, he was responsible for origination, advisory and execution of over 100 equity capital markets and M&A transactions.

Mr. Bønding holds an MSc in Business & Finance from Copenhagen Business School (CBS).

Board Member Mark Johnston

Mr. Johnston joined the Board of Directors of Abacus Medicine in 2019.

Mr. Johnston is Managing Director at Chr. Augustinus Fabrikker Aktieselskab. Previously, Mr. Johnston was Director at Nordic Capital, and Investment Banker at Morgan Stanley.

Mr. Johnston studied finance at Copenhagen Business School and holds a master’s degree in Applied Economics and Finance.

Board Member Michala Fischer-Hansen

Mrs. Fischer-Hansen joined the Board of Directors of Abacus Medicine in 2021.

Mrs. Fischer-Hansen is Executive Vice President at Falck and member of the Executive Management. She brings experience within commercial effectiveness, marketing, pharma economics and market access.

Prior to joining Falck in 2019, Michala Fischer-Hansen had a 19-year international career at Novo Nordisk, i.a. as VP and General Manager for Novo Nordisk operations in Australia and New Zealand., as Corporate Vice President HQ Marketing, and Senior Director at Novo Nordisk Inc. in the US.

Mrs. Fischer-Hansen has studied at the Copenhagen Business School, the Wharton School and Harvard Business School, and holds a master’s degree in international business.